Seagen Inc (SGEN) Stock
SGEN is no longer traded. Seagen was acquired by Pfizer (PFE) on December 14, 2023.
Each SGEN share was exchanged for $229.00 in cash. Prices on this page are historical; the last trade was December 13, 2023 at $228.74.
See Pfizer (PFE) stock →Seagen stock price history
SGEN final trading statistics
- Final close
- $228.74
- Final trading day
- Dec 13, 2023
- Market cap at delisting
- $43.15B
- Shares outstanding
- 188.66M
- Final 52-week range
- $123.77 – $228.96
- Avg. volume (final 3 mo.)
- 1,849,721
- All-time high (split-adj.)
- $228.90 · Dec 2023
- All-time low (split-adj.)
- $2.25 · Apr 2003
- Return since IPO
- +2672.6%
- Beta
- 0.32
- Book value / share
- $13.52
- Price / book
- 16.92
Seagen annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $2.30B | -$750.2M | — |
| FY2022 | $1.96B | -$610.3M | -$3.30 |
| FY2021 | $1.57B | -$674.5M | -$3.70 |
| FY2020 | $2.18B | $613.7M | $3.30 |
| FY2019 | $916.71M | -$63.2M | -$0.98 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Seagen Inc
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
Seagen stock FAQ
What happened to Seagen stock?
Seagen was acquired by Pfizer (PFE) on December 14, 2023. Shareholders received $229.00 in cash for each share. SGEN stock stopped trading on the Nasdaq, with a final close of $228.74 on December 13, 2023.
What did Seagen shareholders receive?
Each SGEN share was converted into $229.00 in cash. The deal was valued at about $43 billion.
Is SGEN stock still trading?
No. SGEN was delisted from the Nasdaq on December 14, 2023 and no longer trades on a U.S. exchange.
What was the last price of SGEN stock?
SGEN closed at $228.74 on its final trading day, December 13, 2023, for a market value of about $43.15B.
What were Seagen's revenue and earnings in its last full fiscal year?
Seagen reported revenue of $2.30B and net income of -$750.2M in fiscal 2023, its last full year as a public company.
When did Seagen go public?
Seagen Inc stock began trading on March 16, 2001.